



News Release

Organon Launches as New Women's Health Company, Opens Asia Pacific HQ in Singapore

Launching with a commitment to listen to women to understand her health needs and help identify solutions that are urgently needed

Singapore, June 3, 2021 – Organon (NYSE: OGN), today celebrates its launch as the only global company of its size focused on women's health. In Asia Pacific including Japan, Organon will be led by Kaja Natland, a highly experienced executive in the biopharmaceutical industry. Employing over 1000 people in the Asia Pacific region, the company will focus on delivering impactful medicines and solutions for a healthier every day for women, their families and communities.

"We are very excited to launch Organon around the world. We build upon our strong foundation of more than 60 established medicines and solutions across a range of areas including reproductive health, heart disease, breast cancer, allergies, and asthma. As a new company, we will begin by listening to women's healthcare needs, big and small, enabling us to explore treatments options -- because we know there is so much more we can do for women and their health." said Kaja.

Together with Kaja, Andreas Jorgensen has been appointed Managing Director for the South, East and Southeast Asia markets. He said, "With more than 2 billion people in this region, we are committed to making a world of difference in women's health every day. The diversity of our business provides an established portfolio so we can look to invest in and advance new medicines and solutions for women that are so urgently needed. We believe the journey to improve women's health is critical to achieving a healthier world."

Singapore is Organon's strategic regional hub

As a strategic hub for Organon, it opened its regional headquarters in Singapore to accelerate business growth in Asia Pacific. This is an affirmation of the company's commitment to the country's strategy to expand and further strengthen the biopharmaceutical industry. Organon Singapore Commercial Director Aman Sood, shared "We are thrilled that Organon has chosen Singapore as its head office for the Asia Pacific and Japan region. As we launch our new company, we are inspired to push past the limits of today and bring healthcare solutions to women and patients across the region."

Diverse Portfolio will Drive Sustainable Growth

At launch, Organon's portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its global US\$6.5 billion in revenue generated outside the U.S. Organon believes it is well positioned for organic low-to-mid-single digit growth from its 2021 base of business.

Organon has three core pillars that will benefit from renewed management focus and commercial investment: women's health, biosimilars and established brands.

Women at the Center: Organon's Approach to Innovation

Organon's R&D philosophy is to build a business around patient needs, with the goal of identifying and advancing healthcare options for women that enable them to live their best lives every day.

"For too long, for too many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause and many others, women have been told to accept and normalize these conditions as a part of life," said Daniel Ruzicka, Medical Lead for Organon Asia Pacific & Japan. "Organon's mission is to change this. We believe this approach will be very successful — the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages."

The company's extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics and devices with the greatest potential to impact women's health.

Wall of Voices

Today, the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. Recognizing the need to listen to and act on women's experiences to address the challenges in women's health, Organon gathered voices from around the world, including many representatives from across the Asia Pacific region to create the "Wall of Voices," a multimedia installation outside of the NYSE sharing powerful perspectives, voices and images. Women everywhere are invited to take the "microphone" to add their voice to the digital "Wall of Voices" at HereForHerHealth.com. To learn more about Organon, please visit www.organon.com.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck (Kenilworth, NJ, USA) to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas around the world. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows that will support investments in future growth opportunities in women's health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

This news release of Organon & Co. (the "company") may include "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying

assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC's Internet site (www.sec.gov).